Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMQ4HIN)

• Drug Name: Cabergoline Drug Info
• Synonyms: Cabaser; Cabaseril; Cabergolina; Cabergolinum; Dostinex; Galastop; Sogilen; Cabergolina [Spanish]; Cabergolinum [Latin]; CG-101; Cabaser (TN); Dostinex (TN); FCE-21336; Cabergoline [USAN:BAN:INN]; Cabergoline (JAN/USAN/INN); (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea
• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 54746
  ChEBI ID: CHEMBL1201087
  CAS Number: CAS 81409-90-7
  TTD Drug ID: D04EGX
  VARIDT Drug ID: DR00069
  INTEDE Drug ID: DR0253
  ACDINA Drug ID: D00086

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Ribosome biogenesis in eukaryotes	2.03	8.61e-3	52/108 (48.15%)	NVL;NOP56;FBL;...
DNA replication	1.92	1.72e-2	34/36 (94.44%)	PCNA;MCM7;MCM2;...
Thiamine metabolism	-1.69	2.30e-2	12/15 (80%)	TPK1;AK5;ACP1;...
Tuberculosis	-1.70	2.23e-2	159/180 (88.33%)	TNF;BCL10;MAPK11;...
Kaposi sarcoma-associated herpesvirus infection	-1.70	2.23e-2	172/193 (89.12%)	EP300;HLA-A;GNG10;...
Metabolism of xenobiotics by cytochrome P450	-1.70	2.15e-2	49/77 (63.64%)	GSTM4;HPGDS;ALDH3B1;...
Type I diabetes mellitus	-1.71	2.23e-2	38/43 (88.37%)	HLA-A;IFNG;HLA-DRA;...
Antigen processing and presentation	-1.73	1.92e-2	60/78 (76.92%)	TNF;HSPA1L;KIR2DL3;...
Cytokine-cytokine receptor interaction	-1.73	1.72e-2	246/295 (83.39%)	CXCR1;IL10RB;TGFB1;...
Pentose phosphate pathway	-1.75	1.36e-2	25/30 (83.33%)	PGLS;ALDOC;ALDOB;...
Lipid and atherosclerosis	-1.76	1.22e-2	190/215 (88.37%)	IFNB1;TLR6;MAPK14;...
NF-kappa B signaling pathway	-1.77	1.11e-2	90/104 (86.54%)	EDA2R;NFKB2;LY96;...
Fluid shear stress and atherosclerosis	-1.78	1.17e-2	123/139 (88.49%)	PRKAA1;MMP9;ACVR2A;...
Leukocyte transendothelial migration	-1.78	1.23e-2	90/114 (78.95%)	PTPN11;JAM2;MYL2;...
Necroptosis	-1.78	1.30e-2	113/159 (71.07%)	STAT5A;CHMP1A;FAS;...
Pathogenic Escherichia coli infection	-1.80	1.05e-2	152/197 (77.16%)	FAS;BAX;ARF6;...
Mineral absorption	-1.80	1.04e-2	48/60 (80%)	TF;ATP7A;FTL;...
NOD-like receptor signaling pathway	-1.80	1.11e-2	145/181 (80.11%)	IFNB1;MAPK14;DEFA5;...
Neutrophil extracellular trap formation	-1.80	1.11e-2	101/189 (53.44%)	TLR8;ITGB2;HDAC9;...
Leishmaniasis	-1.81	1.20e-2	67/77 (87.01%)	MYD88;IFNG;ITGB2;...
Salmonella infection	-1.81	1.21e-2	198/249 (79.52%)	ARF6;AKT3;EXOC2;...
Staphylococcus aureus infection	-1.81	1.32e-2	72/95 (75.79%)	KRT33A;C5;KRT36;...
Viral protein interaction with cytokine and cytokine re...	-1.84	1.23e-2	84/100 (84%)	CXCR1;IL10RB;TNFRSF1B;...
Graft-versus-host disease	-1.85	9.91e-3	32/42 (76.19%)	FAS;TNF;KIR2DL3;...
TNF signaling pathway	-1.87	9.75e-3	103/112 (91.96%)	IFNB1;CREB1;MAPK14;...
Rheumatoid arthritis	-1.88	9.55e-3	78/93 (83.87%)	ATP6V0C;CXCL12;CCL5;...
Natural killer cell mediated cytotoxicity	-1.93	3.72e-3	99/131 (75.57%)	SH3BP2;HLA-A;IFNG;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.95	2.23e-3	62/70 (88.57%)	IKBKG;GIT1;ADAM10;...
Bladder cancer	-1.96	0.00e+0	40/41 (97.56%)	TYMP;HBEGF;NRAS;...
Th17 cell differentiation	-1.97	0.00e+0	95/107 (88.79%)	IFNG;STAT3;CD4;...
IL-17 signaling pathway	-2.09	0.00e+0	84/94 (89.36%)	TRAF3IP2;CCL20;MMP9;...
Osteoclast differentiation	-2.25	0.00e+0	117/127 (92.13%)	SOCS3;FCGR2B;IFNG;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Hide ▲

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	8uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.01uM - 10uM	24H	Show ▼